Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.

Zhao L, He LR, Xi M, Cai MY, Shen JX, Li QQ, Liao YJ, Qian D, Feng ZZ, Zeng YX, Xie D, Liu MZ.

J Transl Med. 2012 Dec 11;10:249. doi: 10.1186/1479-5876-10-249.

2.

The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.

Zhao L, Li QQ, Zhang R, Xi M, Liao YJ, Qian D, He LR, Zeng YX, Xie D, Liu MZ.

Tumour Biol. 2012 Aug;33(4):1115-23. doi: 10.1007/s13277-012-0352-0. Epub 2012 Mar 3.

PMID:
22389159
3.

[Effects and its mechanism of Nimotuzumab on radiosensitivity of esophageal carcinoma ECA-109 and TE-13 cell lines].

Wang J, Wang W, Guo Y, Jing SW, Shang K, Miao MC, Wang J, Wu YJ, Liu LN, Yu JM.

Zhonghua Zhong Liu Za Zhi. 2016 Oct 23;38(10):732-738. doi: 10.3760/cma.j.issn.0253-3766.2016.10.004. Chinese.

PMID:
27784455
4.

Flotillin-1 promotes tumor necrosis factor-α receptor signaling and activation of NF-κB in esophageal squamous cell carcinoma cells.

Song L, Gong H, Lin C, Wang C, Liu L, Wu J, Li M, Li J.

Gastroenterology. 2012 Oct;143(4):995-1005.e12. doi: 10.1053/j.gastro.2012.06.033. Epub 2012 Jun 23.

PMID:
22732732
5.

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status.

Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K.

Br J Cancer. 2008 Feb 26;98(4):749-55. doi: 10.1038/sj.bjc.6604222. Epub 2008 Feb 5.

6.

Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma.

Song H, Pan B, Yi J, Chen L.

Exp Biol Med (Maywood). 2014 May;239(5):529-41. doi: 10.1177/1535370214525315. Epub 2014 Mar 13.

PMID:
24625442
7.

Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma.

Luo LL, Zhao L, Wang YX, Tian XP, Xi M, Shen JX, He LR, Li QQ, Liu SL, Zhang P, Xie D, Liu MZ.

Sci Rep. 2015 Dec 16;5:17336. doi: 10.1038/srep17336.

9.

Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis.

Twarock S, Freudenberger T, Poscher E, Dai G, Jannasch K, Dullin C, Alves F, Prenzel K, Knoefel WT, Stoecklein NH, Savani RC, Homey B, Fischer JW.

Mol Cancer. 2011 Mar 23;10:30. doi: 10.1186/1476-4598-10-30.

10.

Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.

Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R.

Cancer Biol Ther. 2011 Feb 15;11(4):373-82. Epub 2011 Feb 15.

PMID:
21150278
11.

Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma.

Xie F, Liu H, Zhu YH, Qin YR, Dai Y, Zeng T, Chen L, Nie C, Tang H, Li Y, Fu L, Guan XY.

BMC Cancer. 2011 Feb 25;11:86. doi: 10.1186/1471-2407-11-86.

12.

Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.

Zhang G, Zhang Q, Zhang Q, Yin L, Li S, Cheng K, Zhang Y, Xu H, Wu W.

J Cancer Res Clin Oncol. 2010 Apr;136(4):587-94. doi: 10.1007/s00432-009-0693-2. Epub 2009 Oct 13.

PMID:
19823871
13.

Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma.

Luo LL, Zhao L, Xi M, He LR, Shen JX, Li QQ, Liu SL, Zhang P, Xie D, Liu MZ.

Chin J Cancer. 2015 Sep 14;34(11):514-21. doi: 10.1186/s40880-015-0046-2.

14.

High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.

Wang CY, Deng JY, Cai XW, Fu XL, Li Y, Zhou XY, Wu XH, Hu XC, Fan M, Xiang JQ, Zhang YW, Chen HQ, Perez R, Jiang GL, Zhao KL.

Oncotarget. 2015 Jul 30;6(21):18674-82.

15.

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.

Jia J, Cui Y, Lu M, Wang X, Li J, Li J, Li Y, Zhang X, Gao J, Zhou J, Lu Z, Gong J, Yu J, Sun Z, Liu C, Shen L, Zhang X.

Clin Transl Oncol. 2016 Jun;18(6):592-8. doi: 10.1007/s12094-015-1406-8. Epub 2015 Oct 12.

PMID:
26459251
16.

Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.

Qu YY, Hu SL, Xu XY, Wang RZ, Yu HY, Xu JY, Chen L, Dong GL.

PLoS One. 2013 Aug 16;8(8):e70727. doi: 10.1371/journal.pone.0070727. eCollection 2013.

17.

Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.

Lammering G, Lin PS, Contessa JN, Hampton JL, Valerie K, Schmidt-Ullrich RK.

Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):775-84.

PMID:
11697324
18.

The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas.

Qian D, Zhang B, He LR, Cai MY, Mai SJ, Liao YJ, Liu YH, Lin MC, Bian XW, Zeng YX, Huang JJ, Kung HF, Xie D.

J Pathol. 2013 Apr;229(5):765-74. doi: 10.1002/path.4163. Epub 2013 Feb 22.

PMID:
23341363
19.

ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.

Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T.

FEBS Lett. 2005 Aug 1;579(19):4069-75.

20.

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J.

Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6.

Supplemental Content

Support Center